Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants
NCT03507738Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Jul 2018
- Primary completion
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of MT-5625 in rotavirus gastroenteritis (8 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Proportion of subjects with local reactions and reactogenicity events at 7 days and Proportion of subjects reporting adverse events at 28 days. Started Jul 2018; status: completed.
02
Drugs
MT-5625
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT03507738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507738.